ProstaLund AB Market Cap ($716.78K)
Market Cap & Net Worth: ProstaLund AB (PLUN)
ProstaLund AB market cap. ProstaLund AB (ST:PLUN) has a market capitalization of $716.78K (Skr6.66 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #30864 globally and #716 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ProstaLund AB's stock price Skr0.21 by its total outstanding shares 31124052 (31.12 Million). Also see cash flow conversion of ProstaLund AB for how efficiently the company converts equity into cash flow.
ProstaLund AB Market Cap History (2015–2025)
ProstaLund AB market cap history from 2015 to 2025. Data shows change from $35.22 Million to $716.78K (-31.74% CAGR). Check PLUN share price today for real-time trading data and today's change.
ProstaLund AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ProstaLund AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of ProstaLund AB to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.84x
ProstaLund AB's market cap is 1.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $35.22 Million | $13.61 Million | -$9.37 Million | 2.59x | N/A |
| 2016 | $24.15 Million | $14.61 Million | -$11.97 Million | 1.65x | N/A |
| 2017 | $16.59 Million | $13.54 Million | -$16.89 Million | 1.22x | N/A |
| 2018 | $10.88 Million | $13.57 Million | -$12.95 Million | 0.80x | N/A |
| 2019 | $10.85 Million | $12.89 Million | -$10.73 Million | 0.84x | N/A |
| 2020 | $8.94 Million | $12.46 Million | -$10.04 Million | 0.72x | N/A |
| 2021 | $13.87 Million | $17.07 Million | -$7.92 Million | 0.81x | N/A |
| 2022 | $13.38 Million | $17.41 Million | -$11.30 Million | 0.77x | N/A |
| 2023 | $5.46 Million | $22.21 Million | -$17.01 Million | 0.25x | N/A |
| 2024 | $25.25 Million | $13.72 Million | -$22.63 Million | 1.84x | N/A |
Competitor Companies of PLUN by Market Capitalization
Companies near ProstaLund AB in the global market cap rankings as of November 4, 2026. Also see ProstaLund AB total assets for a full breakdown of the balance sheet.
Key companies related to ProstaLund AB by market ranking:
- HCA Healthcare, Inc. (NYSE:HCA): Ranked #283 globally with a market cap of $91.34 Billion USD.
- Fresenius SE & Co. KGaA (XETRA:FRE): Ranked #903 globally with a market cap of $29.19 Billion USD ( €24.97 Billion EUR).
- FRESENIUS SE+CO. ADR 1/4 (F:FREA): Ranked #985 globally with a market cap of $26.87 Billion USD ( €22.98 Billion EUR).
- Tenet Healthcare Corporation (NYSE:THC): Ranked #1213 globally with a market cap of $20.93 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #283 | HCA Healthcare, Inc. | NYSE:HCA | $91.34 Billion | $462.86 |
| #903 | Fresenius SE & Co. KGaA | XETRA:FRE | $29.19 Billion | €48.81 |
| #985 | FRESENIUS SE+CO. ADR 1/4 | F:FREA | $26.87 Billion | €10.20 |
| #1213 | Tenet Healthcare Corporation | NYSE:THC | $20.93 Billion | $266.69 |
Market Capitalization of ProstaLund AB (2015–2025)
Market capitalization of ProstaLund AB from 2015 to today. Between 2015 and today, ProstaLund AB's market cap moved from $35.22 Million to $ 716.78K, with a yearly change of -31.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr716.78K | -97.16% |
| 2024 | Skr25.25 Million | +362.58% |
| 2023 | Skr5.46 Million | -59.20% |
| 2022 | Skr13.38 Million | -3.50% |
| 2021 | Skr13.87 Million | +55.06% |
| 2020 | Skr8.94 Million | -17.59% |
| 2019 | Skr10.85 Million | -0.28% |
| 2018 | Skr10.88 Million | -34.39% |
| 2017 | Skr16.59 Million | -31.32% |
| 2016 | Skr24.15 Million | -31.42% |
| 2015 | Skr35.22 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of ProstaLund AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $716.78K USD |
| MoneyControl | $716.78K USD |
| MarketWatch | $716.78K USD |
| marketcap.company | $716.78K USD |
| Reuters | $716.78K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ProstaLund AB
ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally. It offers CoreTherm, a heat treatment for benign prostate enlargement; CoreFlow, a temporary prostate stent; Oruflow, a urine flow meter; and Schelin Catheter, a medical device intended for intraprostatic and periprostatic injection of legally mark… Read more